drugset / Trial / NCT05120596
First in Human Study of T3P-Y058-739 (T3P)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a first in human, phase I/II open-label, dose-finding, safety, and proof-of-concept clinical trial of T3P-Y058-739, a genetically-modified, live attenuated strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumors.
Timeline
- Start
- 2022-04-26
- Primary completion
- 2027-02-28
- Completion
- 2027-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | T3P-Y058-739 | Other / unclassified | — | Intravenous |